Aeon Biopharma IncNYSE American:AEON
- LAST PRICE0.8790
- TODAY'S CHANGE (%)-0.0009 (-0.1023%)
- Bid / Lots0.7600/ 1
- Ask / Lots0.9250/ 1
- Open / Previous Close0.8796 / 0.8799
- Day Range
- 52 Week Range
- Volume16,968
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AEON |
|---|---|---|
| 09:32 ET | 1770 | 0.8796 |
| 09:39 ET | 164 | 0.879601 |
| 10:22 ET | 100 | 0.88 |
| 10:26 ET | 399 | 0.8767 |
| 10:36 ET | 100 | 0.8826 |
| 10:42 ET | 1000 | 0.8796 |
| 10:49 ET | 100 | 0.8796 |
| 11:16 ET | 1412 | 0.9066 |
| 11:32 ET | 100 | 0.8801 |
| 11:34 ET | 100 | 0.9067 |
| 11:36 ET | 510 | 0.9066 |
| 11:43 ET | 626 | 0.9032 |
| 12:14 ET | 510 | 0.8796 |
| 12:35 ET | 100 | 0.8949 |
| 12:39 ET | 654 | 0.879601 |
| 12:44 ET | 300 | 0.8796 |
| 12:46 ET | 410 | 0.8797 |
| 12:57 ET | 746 | 0.8797 |
| 01:06 ET | 100 | 0.8796 |
| 01:13 ET | 379 | 0.8796 |
| 01:22 ET | 100 | 0.8843 |
| 01:36 ET | 100 | 0.8954 |
| 01:49 ET | 100 | 0.8731 |
| 02:12 ET | 100 | 0.8731 |
| 02:34 ET | 950 | 0.8709 |
| 02:39 ET | 125 | 0.8709 |
| 03:28 ET | 200 | 0.8753 |
| 03:37 ET | 309 | 0.8789 |
| 03:48 ET | 300 | 0.8709 |
| 03:50 ET | 229 | 0.8789 |
| 03:55 ET | 100 | 0.87 |
| 03:57 ET | 400 | 0.878706 |
| 04:00 ET | 454 | 0.879 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aeon Biopharma Inc | 34.8M | -0.1x | --- |
Lantern Pharma Inc | 35.6M | -2.0x | --- |
Akari Therapeutics PLC | 33.8M | -0.8x | --- |
Reviva Pharmaceuticals Holdings, Inc. | 32.3M | -0.8x | --- |
NextCure Inc | 37.2M | -0.6x | --- |
AN2 Therapeutics Inc | 32.2M | -0.5x | --- |
Company Information
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
Contact Information
- Headquarters
- 5 Park Plaza, Suite 1750IRVINE, CA, United States 92614
- Phone
- 949-354-6499
- Fax
- 302-655-5049
Executives
- Chairman Nominee of the Board
- Jost Fischer
- President, Chief Executive Officer, Principal Financial Officer, Director
- Marc Forth
- Executive Vice President, Chief Legal Officer, Corporate Secretary
- Alex Wilson
- Principal Accounting Officer
- Jennifer Sy
- Chief Medical Officer
- Chad Oh
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.5M |
Aeon Biopharma Inc does not pay a dividend. | |
Beta | 0.40 |
EPS | $-8.40 |
Book Value | $-4.12 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
